Six months after the FDA refused to even review Moderna's application, the agency approved the first influenza vaccine ever built on messenger RNA technology. mFlusiva, known during development as mRNA-1010, cleared the FDA on Wednesday, August 5, 2026, for adults 50 and older, positioning it to reach pharmacies and clinics before the 2026-2027 flu season begins.

A regulatory reversal, not a straight path

The approval caps a genuinely turbulent path through the FDA. In mid-February 2026, the agency issued a refusal-to-file decision on Moderna's original application, a procedural rejection that stops a drug review before it formally begins, rather than denying the product outright after full evaluation. That early rejection prompted considerable discussion among clinicians and public health officials about how mRNA vaccine applications were being handled at the agency, particularly given the political backdrop: both President Trump and Health and Human Services Secretary Robert F. Kennedy Jr., a longtime mRNA vaccine skeptic, had publicly criticized mRNA vaccine technology repeatedly since the COVID-19 pandemic, and some experts speculated that criticism may have influenced the FDA's initial refusal to move forward.

Following the rejection, Moderna revised its regulatory strategy, proposing an age-stratified approach: full, standard approval for adults 50 to 64, and a separate accelerated approval pathway for adults 65 and older, paired with a commitment to run an additional postmarketing confirmatory trial in that older group. The FDA accepted that amended application, setting a Prescription Drug User Fee Act target date of August 5, the same day the agency ultimately delivered its approval.

A near-unanimous advisory panel vote paved the way

Before the FDA's own decision, the agency's Vaccines and Related Biological Products Advisory Committee reviewed Moderna's application in June 2026, marking the panel's first review of any new vaccine application since May 2023. The committee voted unanimously, 9 to 0, to recommend mFlusiva for adults 50 and older, a strong and notably clean advisory result that gave the FDA considerable independent expert backing heading into its own formal decision roughly two months later.

What the clinical trial data actually showed

The approval rests primarily on results from the FLUENT trial, a Phase 3, randomized, observer-blind, active-controlled study that enrolled 40,805 adults age 50 and older, randomly assigning participants to receive either the trivalent mRNA vaccine, formulated with 37.5 micrograms total including 12.5 micrograms targeting each of three flu strains, or a licensed standard-dose comparator vaccine.

The headline efficacy result showed mFlusiva achieved 26.6% relative vaccine efficacy compared to the standard-dose comparator, with participants receiving the mRNA vaccine experiencing a lower incidence of laboratory-confirmed, RT-PCR-verified influenza-like illness than those who received the traditional vaccine. That roughly 27% relative improvement in effectiveness over existing standard-dose flu vaccines represents the core clinical case for the new shot, offering meaningfully better protection than what most adults in this age group have had access to in prior flu seasons.

Why the 65-and-older group faced a different, more complicated path

The approval story diverges meaningfully depending on patient age. For adults 50 to 64, the FDA granted a standard, full approval based directly on the FLUENT trial's clinical efficacy data. For adults 65 and older, the agency instead granted accelerated approval, a distinct regulatory pathway that permits licensure based on a surrogate endpoint reasonably likely to predict clinical benefit, rather than requiring direct proof of superior clinical outcomes, paired with a mandatory postmarketing confirmatory trial.

That accelerated approval for the older cohort was supported specifically by superior antibody response data when mFlusiva was compared against Fluzone High-Dose, a comparator vaccine already specifically formulated and marketed for older adults, at both the 29-day and six-month marks following vaccination, rather than by direct clinical endpoint superiority data of the kind supporting the younger age group's full approval. According to Pharmaceutical Technology's detailed regulatory analysis, the review process for this older cohort specifically pivoted after concerns arose about whether an appropriate comparator vaccine had originally been selected for that population, ultimately culminating in the amended, age-stratified filing that led to Wednesday's approval.

Side effects were more frequent, but manageable

Trial data showed mFlusiva produced somewhat more frequent solicited adverse reactions compared to the comparator vaccines used in testing, a pattern broadly consistent with prior mRNA vaccine platforms including Moderna's COVID-19 shots. According to Pharmaceutical Technology's coverage, this increased reactogenicity was described as manageable, with symptoms largely resolving within one to two days following vaccination, and overall safety data showed no novel safety concerns beyond that expected, somewhat elevated short-term reaction profile.

What Moderna's leadership said about the milestone

Moderna CEO Stéphane Bancel framed the approval as validation of the company's broader mRNA technology platform beyond its original COVID-19 vaccine applications. "The FDA approval of mFLUSIVA, our fourth approved product in the United States and the first mRNA-based flu vaccine, demonstrates the continued strength and versatility of our mRNA platform," Bancel said in the company's official announcement. He added, "Flu remains a significant public health challenge, and mFLUSIVA provides an important new option for America's seniors."

That "fourth approved product" framing situates mFlusiva alongside Moderna's existing lineup: Spikevax, its original COVID-19 vaccine now approved in 40 countries; mNEXSPIKE, a newer COVID-19 vaccine; and mRESVIA, its RSV vaccine approved for adults 60 and older in most of the same markets.

A milestone that unlocks two additional stalled programs

Beyond its direct significance as a standalone product, mFlusiva's approval carries meaningful downstream regulatory consequences for Moderna's broader pipeline. According to Tech Times' reporting, the approval simultaneously resolves a regulatory blocking condition that had stalled two other mRNA vaccine programs: it positions mRNA-1083, a combined COVID-19-and-flu vaccine, for resubmission to the FDA after Moderna had previously been awaiting further agency guidance on refiling, and it provides Phase 3 clinical data that Moderna and the Coalition for Epidemic Preparedness Innovations have contractually built into their H5 pandemic influenza vaccine licensure plan, advancing that separate pandemic-preparedness program as well.

Availability and what comes next

Moderna said it expects mFlusiva to reach select U.S. retailers within weeks of the approval, with broader deployment planned ahead of the full 2026-2027 respiratory virus season. The vaccine has also been accepted for regulatory review in the European Union, Canada, and Australia, with Moderna planning additional country-level submissions throughout the remainder of 2026.

For adults 65 and older specifically, continued availability beyond the current approval will depend on Moderna successfully completing its required postmarketing confirmatory trial, which the company has said will run across two full flu seasons and which regulators have already aligned with the company on regarding trial design. Until that confirmatory data arrives, the accelerated approval for this older age group remains conditional in the formal regulatory sense, even though the vaccine is fully available to that population in the meantime.

Why a new flu vaccine platform matters beyond one product

Beyond mFlusiva's specific clinical results, its approval represents a genuine technological milestone for how flu vaccines get developed and updated each year. mRNA-based vaccine platforms allow for considerably more rapid antigenic updating than traditional egg-based or cell-based flu vaccine manufacturing methods, potentially shortening the vaccine development timeline from roughly six months down to two to three months, according to analysis from Pharmaceutical Technology. That kind of speed could prove particularly valuable in years when circulating flu strains shift unexpectedly late in the development cycle, a recurring challenge for traditional flu vaccine manufacturing that mRNA technology's faster reformulation capability is specifically designed to address.

Whether that manufacturing advantage translates into meaningfully improved flu vaccination outcomes at a population level will likely become clearer only once mFlusiva sees a full season of real-world use, but Wednesday's approval, arriving after a rocky regulatory start and against a backdrop of ongoing political controversy over mRNA vaccine technology generally, gives American adults 50 and older a genuinely new option heading into this fall's flu season.

---

*Sources cited in this article include the FDA's official approval action dated August 5, 2026, Moderna's corporate press release, and reporting from Healthcare Dive, BioPharma Dive, Pharmaceutical Technology, Pharmacy Times, PharmExec, and AJMC covering the approval and its regulatory history. All figures reflect reporting available as of August 14, 2026.*